19853-79-3

Basic information

• Product Name: 2,4-dichloro-m-toluidine
• Synonyms: 2,4-dichloro-m-toluidine;(2,4-dichloro-3-methylphenyl)amine hydrochloride;Benzenamine, 2,4-dichloro-3-methyl-;Einecs 243-371-6;(2,4-dichloro-3-methylphenyl)amine(SALTDATA: HCl);2,4-Dichloro-3-Methyl-phenylaMine;2,4-dichloro-3-methylaniline hydrochloride
• CAS NO: 19853-79-3
• Molecular Formula: C₇H₇Cl₂N
• Molecular Weight: 176.04318
• EINECS: 243-371-6
• Mol File: 19853-79-3.mol

Chemical Properties

• Boiling Point: 258.9 °C at 760 mmHg
• Flash Point: 110.4 °C
• Appearance: /
• Density: 1.334 g/cm³
• Vapor Pressure: 0.0133mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.14±0.10(Predicted)
• CAS DataBase Reference: 2,4-dichloro-m-toluidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dichloro-m-toluidine(19853-79-3)
• EPA Substance Registry System: 2,4-dichloro-m-toluidine(19853-79-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 19853-79-3(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis Industry:
2,4-dichloro-m-toluidine is used as a key intermediate in the synthesis of various agricultural chemicals, primarily for the production of herbicides. Its role in this industry is crucial for the development of effective and targeted weed control agents.
Used in Research and Development:
In the scientific community, 2,4-dichloro-m-toluidine is employed as a subject of study to understand its potential as an endocrine disruptor. Researchers are investigating its impact on hormonal systems and the possible consequences of its presence in the environment.
Used in Environmental Studies:
2,4-dichloro-m-toluidine is also utilized in environmental research to assess its effects on aquatic organisms. This is important for evaluating the ecological risks associated with the use of herbicides that contain this compound and for developing strategies to mitigate any negative impacts on aquatic ecosystems.

InChI:InChI=1/C7H7Cl2N/c1-4-5(8)2-3-6(10)7(4)9/h2-3H,10H2,1H3

Upstream product

• 56961-87-6 N-(2-chloro-3-methylphenyl)acetamide 
• 7647-01-0 hydrogenchloride 
• 109101-04-4 benzenesulfonic acid-(2,4-dichloro-3-methyl-anilide) 
• 118-69-4 2,6-dichlorotoluene 
• 19853-80-6 acetic acid-(2,4-dichloro-3-methyl-anilide) 
• 56961-88-7 N-(4-chloro-3-methylphenyl)acetamide 
• 29682-46-0 2,6-dichloro-3-nitrotoluene 

Downstream Products

• 500881-08-3 2,3,6-trichloro-5-nitro-toluene 
• 115423-97-7 2,3,6-trichloro-4,5-dinitro-toluene 
• 50-31-7 2,3,6-TBA 
• 190722-81-7 Acetic acid 2,6-dichloro-3-heptadecafluorooctyl-benzyl ester 
• 190722-70-4 2,6-Dichloro-3-heptadecafluorooctyl-benzaldehyde 
• 190722-82-8 (2,6-Dichloro-3-heptadecafluorooctyl-phenyl)-methanol 
• 190722-80-6 1,3-Dichloro-4-heptadecafluorooctyl-2-methyl-benzene 
• 190722-79-3 2,6-dichloro-3-iodotoluene 
• 2077-46-5 1,2,4-trichloro-3-methylbenzene 
• 1257599-71-5 C₁₄H₁₃Cl₂N₃O 

Relevant articles and documents

Highly selective hydrogenation of aromatic chloronitro compounds to aromatic chloroamines with ionic-liquid-like copolymer stabilized platinum nanocatalysts in ionic liquids

Platinum nanoparticles (PtNPs stabilized by an ionic-liquid-like-copolymer (IP) immobilized in various ionic liquids (ILs)) effectively catalyze the selective hydrogenation of aromatic chloronitro compounds to aromatic chloroamines, a reaction of considerable commercial significance. The preparation of 2,4-dichloro-3-aminophenol (DAP) has been primarily studied due to its important industrial applications. DAP is usually prepared from 2,4-dichloro-3-nitrophenol (DNP) by reduction with hydrogen using Ni- or Pt-based catalysts. Compared to reactions in molecular (organic) solvents, the ILs system provides superior selectivity with functionalized ILs containing an alcohol group demonstrating the best recyclability, and ultimately achieving a turnover number of 2025 which is 750 fold higher than Raney nickel catalyst. A universal catalyst-ionic liquid system for the conversion of aromatic chloronitro compounds to aromatic chloroamines was also established. TEM, XPS, IR spectroscopy were used to characterize the morphology of the nanocatalysts allowing their structure to be correlated to their activity.

TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS

There is provided compounds of formula (I) wherein W is an optionally substituted aryl or heteroaryl group, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15- lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

Compounds of formula (I), where m, n, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

Epoxidation of alkenes under liquid-liquid biphasic conditions: Synthesis and catalytic activity of Mn(III)-tetraarylporphyrins bearing perfluoroalkyl tails

Four tetraarylporphyrins bearing one n-C8F17 chain on each meso-aryl group have been synthesized, The Mn(III)-complexes of these new compounds (Mn-1 - Mn-4) were used as catalysts in alkene epoxidations carried out under aqueous-organic biphasic conditions. High epoxide yields were obtained with catalysts in which, along with perfluoroalkyl chains, bulky substituents were present at appropriate positions. The expected general enhancement of stability and catalytic activity due to the electron-withdrawing effect of n-C8F17 substituents was not observed. However, Mn-4 was found to be an exceptionally active catalyst for NaOCl promoted epoxidation of poorly reactive linear α-alkenes.

IMIDAZO [1,2-A] PYRIDINES AND THEIR PHARMACEUTICAL USE

The invention relates to novel bradykinin antagonists of the formula: STR1 wherein R 1 is halogen,R 2 and R 3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R 4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R 11, in which R 11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.